0000867840 false --06-30 2023 Q1 0000867840 2022-07-01 2022-09-30 0000867840 2022-11-14 0000867840 2022-09-30 0000867840 2022-06-30 0000867840 2021-07-01 2021-09-30 0000867840 2021-01-01 2021-09-30 0000867840 us-gaap:CommonStockMember 2022-06-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000867840 PEYE:CommonStockSubscribedMember 2022-06-30 0000867840 us-gaap:RetainedEarningsMember 2022-06-30 0000867840 us-gaap:CommonStockMember 2021-06-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000867840 PEYE:CommonStockSubscribedMember 2021-06-30 0000867840 us-gaap:RetainedEarningsMember 2021-06-30 0000867840 2021-06-30 0000867840 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000867840 PEYE:CommonStockSubscribedMember 2022-07-01 2022-09-30 0000867840 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000867840 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000867840 PEYE:CommonStockSubscribedMember 2021-07-01 2021-09-30 0000867840 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000867840 us-gaap:CommonStockMember 2022-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000867840 PEYE:CommonStockSubscribedMember 2022-09-30 0000867840 us-gaap:RetainedEarningsMember 2022-09-30 0000867840 us-gaap:CommonStockMember 2021-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000867840 PEYE:CommonStockSubscribedMember 2021-09-30 0000867840 us-gaap:RetainedEarningsMember 2021-09-30 0000867840 2021-09-30 0000867840 PEYE:LighthouseImagingMember 2021-10-01 2021-10-04 0000867840 2022-10-01 0000867840 PEYE:MainStreetBankMember 2021-10-04 0000867840 PEYE:MainStreetBankMember 2021-10-04 0000867840 PEYE:MainStreetBankMember 2022-09-30 0000867840 PEYE:MainStreetBankMember 2022-07-01 2022-09-30 0000867840 PEYE:MainStreetBankMember 2022-09-30 0000867840 PEYE:ManufacturingEquipmentMember 2021-03-31 0000867840 PEYE:ManufacturingEquipment2Member 2020-01-31 0000867840 PEYE:ElPasoTexasMember 2022-07-01 2022-09-30 0000867840 PEYE:ElPasoTexasMember 2021-07-01 2021-09-30 0000867840 PEYE:WindhamMaineMember 2022-09-30 0000867840 PEYE:WindhamMaineLeaseMember 2022-07-01 2022-09-30 0000867840 PEYE:GardnerMaMember 2022-07-01 2022-09-30 0000867840 PEYE:GardnerMaMember 2021-07-01 2021-09-30 0000867840 us-gaap:CapitalLeaseObligationsMember 2022-09-30 0000867840 PEYE:OperatingLeaseMember 2022-09-30 0000867840 us-gaap:StockOptionMember 2022-09-30 0000867840 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000867840 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000867840 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000867840 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000867840 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000867840 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000867840 us-gaap:StockOptionMember 2022-06-30 0000867840 us-gaap:StockOptionMember 2022-07-01 2022-09-30 0000867840 PEYE:Option1Member 2022-09-30 0000867840 PEYE:Option1Member 2022-07-01 2022-09-30 0000867840 PEYE:Option2Member 2022-09-30 0000867840 PEYE:Option2Member 2022-07-01 2022-09-30 0000867840 PEYE:Option3Member 2022-09-30 0000867840 PEYE:Option3Member 2022-07-01 2022-09-30 0000867840 PEYE:Option4Member 2022-09-30 0000867840 PEYE:Option4Member 2022-07-01 2022-09-30 0000867840 PEYE:Option5Member 2022-09-30 0000867840 PEYE:Option5Member 2022-07-01 2022-09-30 0000867840 PEYE:Option6Member 2022-09-30 0000867840 PEYE:Option6Member 2022-07-01 2022-09-30 0000867840 PEYE:Option7Member 2022-09-30 0000867840 PEYE:Option7Member 2022-07-01 2022-09-30 0000867840 PEYE:Option8Member 2022-09-30 0000867840 PEYE:Option8Member 2022-07-01 2022-09-30 0000867840 PEYE:Option9Member 2022-09-30 0000867840 PEYE:Option9Member 2022-07-01 2022-09-30 0000867840 PEYE:Option10Member 2022-09-30 0000867840 PEYE:Option10Member 2022-07-01 2022-09-30 0000867840 PEYE:Option11Member 2022-09-30 0000867840 PEYE:Option11Member 2022-07-01 2022-09-30 0000867840 PEYE:Option12Member 2022-09-30 0000867840 PEYE:Option12Member 2022-07-01 2022-09-30 0000867840 PEYE:Option13Member 2022-09-30 0000867840 PEYE:Option13Member 2022-07-01 2022-09-30 0000867840 PEYE:Option14Member 2022-09-30 0000867840 PEYE:Option14Member 2022-07-01 2022-09-30 0000867840 PEYE:Option15Member 2022-09-30 0000867840 PEYE:Option15Member 2022-07-01 2022-09-30 0000867840 PEYE:Option16Member 2022-09-30 0000867840 PEYE:Option16Member 2022-07-01 2022-09-30 0000867840 PEYE:Option17Member 2022-09-30 0000867840 PEYE:Option17Member 2022-07-01 2022-09-30 0000867840 PEYE:Option18Member 2022-09-30 0000867840 PEYE:Option18Member 2022-07-01 2022-09-30 0000867840 PEYE:OptionsMember srt:MinimumMember 2022-09-30 0000867840 PEYE:OptionsMember srt:MaximumMember 2022-09-30 0000867840 PEYE:OptionsMember 2022-09-30 0000867840 PEYE:OptionsMember 2022-07-01 2022-09-30 0000867840 PEYE:EngineeringDesignServicesMember 2022-07-01 2022-09-30 0000867840 PEYE:EngineeringDesignServicesMember 2021-07-01 2021-09-30 0000867840 PEYE:OpticalComponentsMember 2022-07-01 2022-09-30 0000867840 PEYE:OpticalComponentsMember 2021-07-01 2021-09-30 0000867840 PEYE:MedicalDeviceMember 2022-07-01 2022-09-30 0000867840 PEYE:MedicalDeviceMember 2021-07-01 2021-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

           

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

or

 

☐  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

 

Commission File Number: 001-10647

 

PRECISION OPTICS CORPORATION, INC.

(Exact name of registrant as specified in its charter)

 

Massachusetts 04-2795294
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

22 East Broadway, Gardner, Massachusetts 01440-3338

(Address of principal executive offices) (Zip Code)

 

(978) 630-1800

(Registrants telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value PEYE OTCQB

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

   

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer ☒   Smaller reporting company ☒
      Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares outstanding of the issuers common stock, par value $0.01 per share, at November 14, 2022 was 5,638,302 shares.

 

 

 

   

 

 

PRECISION OPTICS CORPORATION, INC.

 

Table of Contents

 

  Page
PART I FINANCIAL INFORMATION 3
Item 1. Financial Statements 3
Consolidated Balance Sheets at September 30, 2022 and June 30, 2022 3
Consolidated Statements of Operations for the Three Months Ended September 30, 2022 and 2021 4
Consolidated Statements of Stockholders’ Equity for the Three Months Ended September 30, 2022 and 2021 5
Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2022 and 2021 6
Notes to Consolidated Financial Statements 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
Item 3. Quantitative and Qualitative Disclosures About Market Risk 18
Item 4. Controls and Procedures 18
   
PART II OTHER INFORMATION 19
Item 1. Legal Proceedings 19
Item 1A. Risk Factors 19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19
Item 3. Defaults Upon Senior Securities 19
Item 4. Mine Safety Disclosures (Not applicable.) 19
Item 5. Other Information 19
Item 6. Exhibits 20

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

           
   September 30,   June 30, 
   2022   2022 
ASSETS          
Current Assets:          
Cash and cash equivalents  $673,502   $605,749 
Accounts receivable, net of allowance for doubtful accounts of $50,114 at September 30, 2022 and $44,135 at June 30, 2022   3,414,685    2,663,872 
Inventories   2,755,660    3,022,147 
Prepaid expenses   187,498    213,448 
Total current assets   7,031,345    6,505,216 
           
Fixed Assets:          
Machinery and equipment   3,222,406    3,215,412 
Leasehold improvements   847,363    843,903 
Furniture and fixtures   225,564    219,999 
Total Fixed Assets   4,295,333    4,279,314 
Less—Accumulated depreciation and amortization   3,704,254    3,651,843 
Net fixed assets   591,079    627,471 
           
Operating lease right-to-use asset   478,645    517,725 
Patents, net   242,553    229,398 
Goodwill   8,824,210    8,824,210 
           
TOTAL ASSETS  $17,167,832   $16,704,020 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Current portion of capital lease obligation  $41,318   $40,705 
Current maturities of long-term debt   371,429    367,714 
Current portion of acquisition earn out liability   166,667    166,667 
Accounts payable   2,305,907    2,239,175 
Customer advances   1,032,891    905,113 
Accrued compensation and other   1,117,000    716,702 
Operating lease liability   160,923    150,565 
Total current liabilities   5,196,135    4,586,641 
           
Capital lease obligation, net of current portion   101,128    111,691 
Long-term debt, net of current maturities and debt issuance costs   1,865,498    1,961,141 
Acquisition earn out liability, net of current portion   714,375    705,892 
Operating lease liability, net of current portion   317,722    367,160 
           
Stockholders’ Equity:          
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 16,915,089 shares at September 30, 2022 and June 30, 2022   169,150    169,150 
Additional paid-in capital   56,971,729    56,896,739 
Accumulated deficit   (48,167,905)   (48,094,394)
Total stockholders’ equity   8,972,974    8,971,495 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $17,167,832   $16,704,020 

 

The accompanying notes are an integral part of these consolidated interim financial statements.

 

 

 

 3 

 

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED

SEPTEMBER 30, 2022 AND 2021

(UNAUDITED)

 

         
   Three Months
Ended September 30,		 
   2022   2021 
Revenues  $5,085,301   $2,336,344 
           
Cost of Goods Sold   3,360,647    1,697,312 
Gross Profit   1,724,654    639,032 
           
Research and Development Expenses, net   245,477    105,186 
           
Selling, General and Administrative Expenses   1,495,766    933,624 
Business acquisition expenses   –    172,174 
Total Operating Expenses   1,741,243    1,210,984 
           
Operating Loss   (16,589)   (571,952)
           
Interest Expense   (56,922)   (4,849)
           
Net Loss  $(73,511)  $(576,801)
           
Loss Per Share:          
Basic and Fully Diluted  $(0.00)  $(0.04)
           
Weighted Average Common Shares Outstanding:          
Basic   16,915,089    13,282,476 
Fully Diluted   16,915,089    13,282,476 

 

The accompanying notes are an integral part of these consolidated interim financial statements.

 

 

 

 4 

 

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED

SEPTEMBER 30, 2022 AND 2021

(UNAUDITED)

 

                         
       Three Month Period Ended September 30, 2022     
   Number of
Shares		   Common
Stock		   Additional
Paid-in
Capital		  

Common

Stock

Subscribed

   Accumulated
Deficit		   Total
Stockholders’
Equity		 
                         
Balance, July 1, 2022   16,915,089   $169,150   $56,896,739   $–   $(48,094,394)  $8,971,495 
Stock-based compensation   –    –    74,990    –    –    74,990 
Net loss   –    –    –    –    (73,511)   (73,511)
Balance, September 30, 2022   16,915,089   $169,150   $56,971,729   $–   $(48,167,905)  $8,972,974 

 

 

                         
       Three Month Period Ended September 30, 2021     
   Number of
Shares		   Common
Stock		   Additional
Paid-in
Capital		  

Common

Stock

Subscribed

   Accumulated
Deficit		   Total
Stockholders’
Equity		 
                         
Balance, July 1, 2021   13,282,476   $132,825   $50,464,280   $–   $(47,165,978)  $3,431,127 
Stock-based compensation   –    –    160,071    –    –    160,071 
Proceeds from private placement of common stock subscribed, net of estimated issuance costs of $10,000   –    –    (10,000)   1,030,000    –    1,020,000 
Net loss   –    –    –    –    (576,801)   (576,801)
Balance, September 30, 2021   13,282,476   $132,825   $50,614,351   $1,030,000   $(47,742,779)  $4,034,397 

 

The accompanying notes are an integral part of these consolidated interim financial statements.

 

 

 

 5 

 

 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED

SEPTEMBER 30, 2022 AND 2021

(UNAUDITED)

 

         
   Three Months
Ended September 30,		 
   2022   2021 
Cash Flows from Operating Activities:          
Net Loss  $(73,511)  $(576,801)
Adjustments to reconcile net loss to net cash used in by operating activities -          
Depreciation and amortization   52,411    42,280 
Stock-based compensation expense   74,990    160,071 
Non-cash interest expense   9,412    – 
Changes in operating assets and liabilities -          
Accounts receivable, net   (750,813)   167,563 
Inventories, net   266,487    (235,495)
Prepaid expenses   25,950    8,309 
Accounts payable   66,732    81,091 
Customer advances   127,778    (113,512)
Accrued compensation and other   400,298    284,154 
Net cash provided by (used in) operating activities   199,734    (182,340)
           
Cash Flows from Investing Activities:          
Purchases of fixed assets   (16,019)   (24,325)
Additional patent costs   (13,155)   (6,041)
Net cash used in investing activities   (29,174)   (30,366)
           
Cash Flows from Financing Activities:          
Payment of capital lease obligation   (9,950)   (9,375)
Payments of long-term debt   (92,857)   – 
Gross Proceeds from private placement of common stock subscribed   –    1,030,000 
Net cash (used in) provided by financing activities   (102,807)   1,020,625 
           
Net increase in cash and cash equivalents   67,753    807,919 
Cash and cash equivalents, beginning of period   605,749    861,650 
           
Cash and cash equivalents, end of period  $673,502   $1,669,569 
           
Supplemental disclosure of non-cash financing activities:          
Offering costs included in accrued compensation and other  $–   $10,000 

 

The accompanying notes are an integral part of these consolidated interim financial statements.

 

 

 

 

 6 

 

 

PRECISION OPTICS CORPORATION, INC.

NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

 

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation and Operations

 

The accompanying consolidated financial statements include the accounts of Precision Optics Corporation, Inc. and its wholly-owned subsidiaries (the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the first quarter of the Company’s fiscal year 2023. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company’s consolidated financial statements for the year ended June 30, 2022, together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company’s 2022 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 27, 2022.

 

Use of Estimates

 

The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

 

Income (Loss) Per Share

 

Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options. For the three months ended September 30, 2022, the effect of such securities was antidilutive and not included in the fully diluted calculation because of the net loss generated during those periods.

 

The following is the calculation of income (loss) per share for the three months ended September 30, 2022 and 2021: 

        
   Three Months
Ended September 30,		 
   2022   2021 
Net Income (Loss) Basic and Fully Diluted  $(73,511)  $(576,801)
           
Weighted Average Shares Outstanding          
Basic and Fully Diluted   16,915,089    13,282,476 
           
Loss Per Share - Basic and Fully Diluted  $(0.00)  $(0.04)

  

The number of shares issuable upon the exercise of outstanding stock options that were excluded from the computation as their effect was antidilutive was approximately 2,714,000 and 2,563,200 for the three months ended September 30, 2022 and 2021, respectively.

 

 

 

 7 

 

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

  

In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment. Based on this evaluation, a full valuation reserve has been provided for the deferred tax assets.

 

Goodwill and Patents

 

Long-lived assets such as goodwill and patents are capitalized when acquired and reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No such impairments of goodwill or patents have been estimated by management as of September 30, 2022.

 

2. BUSINESS ACQUISITION

 

On October 4, 2021, the Company acquired substantially all of the assets of Lighthouse Imaging, LLC, of Windham, Maine, a medical optics and digital imaging business operating as a designer and manufacturer of advanced optical imaging systems and accessories with a strong expertise in electrical engineering and development of end-to-end medical visualization devices. The actual results of operations of the Lighthouse division are included in the accompanying consolidated financial statements as of, and for the three months ended, September 30, 2022.

 

The purchase price for Lighthouse Imaging included $1,500,000 as potential earn-out consideration over the subsequent two year period, contingent on the Lighthouse division meeting specified annual gross profit targets. The Lighthouse division did not meet the target for the first $750,000 portion of the earn-out, and the contingent liability associated with that portion was reversed and recognized as other income in the fiscal quarter ended June 30, 2022. The second $750,000 portion of the earn-out contingent liability will be paid if the target level of gross profit is earned by the Lighthouse division for the period from October 1, 2022 through September 30, 2023.

 

Consolidated unaudited pro forma results of operations for the Company are presented below assuming that the acquisition of the Lighthouse division had occurred on July 1, 2021. Pro forma operating results include net adjustments resulting from the acquisition transaction during the three months ended September 30, 2021.

          
   Three Months
Ended September 30,		 
   2022   2021 
   (Actual)   (Pro Forma) 
         
Revenues  $5,085,301   $3,780,681 
Net Loss  $(73,511)  $(519,506)
Loss per Share          
Basic and diluted  $(0.00)  $(0.03)

 

Pro forma financial information is not necessarily indicative of the Company’s actual results of operations if the acquisition had been completed at the date indicated, nor is it necessarily an indication of future operating results. Amounts do not include any operating efficiencies or cost saving that the Company believes may be achievable.

 

 

 

 8 

 

 

 

3. INVENTORIES

 

Inventories are stated at the lower of cost (first-in, first-out) or market and consisted of the following:

        
   September 30,
2022		   June 30,
2022		 
Raw Materials  $1,075,948   $1,414,996 
Work-In-Progress   469,647    460,460 
Finished Goods   1,210,065    1,146,691 
Total Inventories  $2,755,660   $3,022,147 

 

4. BANK FINANCING ACTIVITIES

 

Bank Line of Credit

 

On October 4, 2021, the Company entered into a Loan Agreement with Main Street Bank of Marlborough, Massachusetts, which provided for a $2,600,000 Term Loan and a $250,000 Revolving Line of Credit Loan Facility, which was increased to $500,000 effective May 17, 2022. The $500,000 line of credit is due on demand and had no borrowings outstanding at September 30, 2022. Borrowings under the line of credit bear interest payable monthly at the prime lending rate plus 1.5% per annum, or 7.75% as of September 30, 2022, and shall not be less than 4.75% per annum. Borrowings under the line of credit are limited to the borrowing base comprised of a percentage of accounts receivable and inventory and are secured by all the assets of the Company.

 

Long-Term Debt

 

Long-term debt consists of the following at September 30, 2022:

     
   Amount 
Term Loan Note payable to Main Street Bank with monthly principal payments of $30,952.38 plus interest at the rate of 7.00% as of September 30, 2022. Secured by all assets of the Company, and subject to certain periodic reporting to the bank, an annual minimum EBITDA plus stock based compensation to debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023, and other conditions. The Term Loan Note matures on October 15, 2028.  $2,259,524 
      
Less current maturities   (371,429)
Less debt issuance costs, net of accumulated amortization of $929   (22,597)
Long-term debt, net of current portion of debt issuance costs  $1,865,498 

 

 

 

 9 

 

 

At September 30, 2022 principal payments due on the Term Loan Note payable are as follows:

    
Fiscal Year Ending June 30:    
2023  $278,572 
2024   371,429 
2025   371,429 
2026   371,429 
2027   371,429 
Thereafter    495,236 
      
Total long term debt   $2,259,524 

 

 

5. LEASE OBLIGATIONS

 

In March 2021 the Company entered into a five-year capital lease in the amount of $161,977 for manufacturing equipment. In January 2020, the Company entered into a five-year capital lease for $47,750 for manufacturing equipment. The net book value of fixed assets under capital lease obligations as of September 30, 2022 is $135,667.

  

On July 1, 2019 the Company entered into a three-year operating lease for its facility in El Paso, Texas, and in February 2022 the Company entered into an extension of the lease for an additional three years through June 2025. Remaining minimum lease payments at September 30, 2022 total $123,842. Total rent expense including base rent and common area expenses was $11,630 and $13,997 during the fiscal quarters ended September 30, 2022 and 2021, respectively. On October 4, 2021 the Company assumed the remaining term of the Windham, Maine lease as part of the Lighthouse acquisition. The lease expires on July 31, 2025. Remaining minimum lease payments at September 30, 2022 total $390,229. Total rent expense including base rent and common area expenses was $35,017 during the fiscal quarter ended September 30, 2022. Included in the accompanying balance sheet at September 30, 2022 is a right-of-use asset of $478,645 and current and long-term right-of-use operating lease liabilities of $160,924 and $317,722, respectively.

 

At September 30, 2022 future minimum lease payments under the capital lease and operating lease obligations are as follows: 

          
Fiscal Year Ending June 30:  Capital Leases   Operating Lease 
2023  $36,464   $136,167 
2024   48,619    182,652 
2025   43,917    183,775 
2026   28,028    11,477 
Total Minimum Payments   157,028   $514,071 
Less: amount representing interest   14,582      
Present value of minimum lease payments   142,446      
Less: current portion   41,318      
   $101,128      

 

The Company’s operating leases for its Gardner, Massachusetts office, production and storage spaces plus an equipment lease have expired and are continuing on a month-to-month tenant at will basis. Rent expense on these operating leases was $50,826 and $51,277 for the fiscal quarter ended September 30, 2022 and 2021, respectively.

 

 

 

 10 

 

 

 

6. STOCK-BASED COMPENSATION

 

Stock Options

 

The following table summarizes stock-based compensation expense for the three months ended September 30, 2022 and 2021: The share amounts and prices shown below do not reflect adjustment for a 1-for-3 reverse stock split that took effect after the close of business on November 1, 2022.

        
   Three Months
Ended September 30,		 
   2022   2021 
Cost of Goods Sold  $6,298   $28,415 
Research and Development Expenses   30,756    43,489 
Selling, General and Administrative Expenses   37,936    88,167 
   $74,990   $160,071 

 

No compensation has been capitalized because such amounts would have been immaterial.

  

The following tables summarize stock option activity for the three months ended September 30 2022:

               
    Options Outstanding 
    Number of
Shares		    Weighted Average
Exercise Price		    Weighted Average
Contractual Life		 
Outstanding at June 30, 2022   2,714,000   $1.33    7.08 years 
Exercised, Granted and Cancelled   –    –    – 
Outstanding at September 30, 2022   2,714,000   $1.33    6.83 years 

 

 

 

 11 

 

  

Information related to the stock options outstanding as of September 30, 2022 is as follows:

                                           
Range of
Exercise Prices		     Number of
Shares		     Weighted-
Average
Remaining
Contractual Life
(years)		     Weighted-
Average
Exercise Price		     Exercisable
Number of
Shares		     Exercisable
Weighted-
Average
Exercise Price		  
$ 0.48       60,000       3.50     $ 0.48       60,000     $ 0.48  
$ 0.50       80,000       3.72     $ 0.50       80,000     $ 0.50  
$ 0.55       15,000       5.51     $ 0.55       15,000     $ 0.55  
$ 0.70       100,000       5.84     $ 0.70       100,000     $ 0.70  
$ 0.73       630,000       4.41     $ 0.73       630,000     $ 0.73  
$ 0.85       6,000       0.26     $ 0.85       6,000     $ 0.85  
$ 0.90       36,000       1.69     $ 0.90       36,000     $ 0.90  
$ 1.25       45,000       7.47     $ 1.25       30,000     $ 1.25  
$ 1.30       441,000       6.70     $ 1.30       431,500     $ 1.30  
$ 1.40       70,000       8.13     $ 1.40       70,000     $ 1.40  
$ 1.42       100,000       6.95     $ 1.42       100,000     $ 1.42  
$ 1.45       5,000       8.44     $ 1.45       1,667     $ 1.45  
$ 1.50       70,000       7.19     $ 1.50       70,000     $ 1.50  
$ 1.68       540,000       8.68     $ 1.68       540,000     $ 1.68  
$ 1.87       30,000       9.61     $ 1.87       –     $ –  
$ 2.00       100,000       8.57     $ 2.00       10,000     $ 2.00  
$ 2.09       246,000       9.36     $ 2.09       –     $ –  
$ 2.26       140,000       9.14     $ 2.26       90,000     $ 2.26  
$ 0.48–2.26       2,714,000       6.83     $ 1.33       2,270,167     $ 1.20  

 

The aggregate intrinsic value of the Company’s in-the-money outstanding and exercisable options as of September 30, 2022 was $1,982,850 and $1,951,825, respectively.

   

7. REVENUE RECOGNITION

 

Revenues are recognized as the performance obligations to deliver products or services are satisfied and are recorded based on the amount of consideration the Company expects to receive in exchange for satisfying the performance obligations. Most of the Company’s products and services are marketed to medical device companies with approximately 85% of sales to customers in the United States. Products and services are primarily transferred to customers at a point in time based upon when services are performed or product is shipped. Other selling costs to obtain and fulfill contracts are expensed as incurred due to the short-term nature of a majority of its contracts. The Company extends terms of payment to its customers based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling costs charged to customers are included in revenues.

 

 

 

 12 

 

 

The Company disaggregates revenues by product and service types as it believes it best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Revenues are comprised of the following for the three months ended September 30, 2022 and 2021:

        
   Three Months
Ended September 30,		 
   2022   2021 
Engineering Design Services  $1,642,967   $373,316 
Optical Components   2,652,681    1,538,932 
Medical Device Products & Assemblies   789,653    424,096 
   $5,085,301   $2,336,344 

 

Contract Assets and Liabilities

 

The nature of the Company’s products and services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or service is provided to a customer. The Company’s costs to obtain contracts are typically in the form of sales commissions paid to employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of September 30, 2022, there were no contract assets recorded in the Company’s Consolidated Balance Sheets.

  

The Company’s contract liabilities arise from unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of our performance obligations. The Company generally satisfies performance obligations within one year from the contract inception date.

  

Contract liabilities, which were recorded as customer advances in the Company’s Consolidated Balance Sheets, and unearned revenue are comprised of the following:

          
  

Three Months

Ended September 30,

 
   2022   2021 
Contract liabilities, beginning of period  $905,113   $450,084 
Unearned revenue received from customers   455,613    205,389 
Revenue recognized   (327,835)   (318,901)
Contract liabilities, end of period  $1,032,891   $336,572 

 

 

8. COVID-19 PANDEMIC

 

The COVID-19 world-wide pandemic that began during the quarter ended March 31, 2020 and the domestic and international impact of policy decisions being made in major countries around the world has had, and could continue to have, an adverse impact on the Company’s sources of supply, current and future orders from its customers, collection of amounts owed to the Company from its customers, its internal operating procedures, and the Company’s overall financial condition.

 

 

 

 

 13 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and with our audited consolidated financial statements for the year ended June 30, 2022 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 27, 2022.

 

This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this report, the words anticipate, suggest, estimate, plan, project, continue, ongoing, potential, expect, predict, believe, intend, may, will, should, could, would and similar expressions are intended to identify forward-looking statements. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the risks described in this report, the risks described in our Annual Report on Form 10-K for the year ended June 30, 2022 and other reports we file with the Securities and Exchange Commission. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made. We do not intend to update any of the forward-looking statements after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.

 

Overview

 

We have been a developer and manufacturer of advanced optical instruments since 1982. Our medical instrumentation line includes traditional endoscopes and endocouplers as well as other custom imaging and illumination products for use in minimally invasive surgical procedures. Much of our recent development efforts have been targeted at the development of next generation endoscopes. We selectively execute internal research and development programs to develop next generation capabilities for designing and manufacturing 3D endoscopes and very small MicroprecisionTM lenses, anticipating future requirements as the surgical community continues to demand smaller and more enhanced imaging systems for minimally invasive surgery.

 

As Ross Optical Industries of El Paso, Texas we also operate as a supplier of custom optical components and assemblies for military and defense, medical and various other industrial applications. All products sold by us under the Ross Optical name include a custom or catalog optic, which is sourced through our extensive domestic and worldwide network of optical fabrication companies. Most systems make use of optical lenses, prisms, mirrors and windows and range from individual optical components to complex mechano-optical assemblies. Products often include thin film optical coatings that are applied using our in-house coating department.

 

As Lighthouse Imaging of Windham, Maine we also operate as a manufacturer of advanced optical imaging systems and accessories. We have a strong expertise in electrical engineering and development of end-to-end medical visualization devices. Product development competencies at Lighthouse Imaging include Systems, Optical, Mechanical, Electrical and Process Development Engineering. Our product development team has extensive experience developing visualization systems that are used in a variety of clinical applications. Lighthouse Imaging is an industry leader in chip on tip visualization systems.

 

Approximately 32% our business during the three months ended September 30, 2022 is from engineering services (primarily relating to the design of medical device optical assemblies), 52% from the sale of both internally manufactured and purchased optical components, and 16% from the manufacture of optical assemblies and sub-assemblies (primarily for medical device instrument applications). Our proprietary medical instrumentation line, unique custom design and manufacturing capabilities, and expert electrical engineering and development services have generated orders for traditional proprietary endoscopes and endocouplers as well as for custom imaging and illumination products for use in minimally invasive surgical procedures. We design and manufacture 3D endoscopes and very small MicroprecisionTM lenses, assemblies and complete medical devices to meet the surgical community’s continuing demand for smaller, disposable, and more enhanced imaging systems for minimally invasive surgery.

  

 

 

 14 

 

 

We are registered to the ISO 9001:2015 and ISO 13485:2016 Quality Standards and comply with the FDA Good Manufacturing Practices and the European Union Medical Device Directive for CE marking of our medical products.

  

Our internet websites are www.poci.com, www.rossoptical.com, and www.lighthouseoptics.com. Information on our websites is not intended to be integrated into this report. Investors and others should note that we announce material financial information using our company websites (www.poci.com; www.rossoptical.com; www.lighthouseoptics.com), our investor relations website, SEC filings, press releases, public conference calls and webcasts. Information about Precision Optics, our business, and our results of operations may also be announced by social media posts on our Ross Optical and Lighthouse LinkedIn pages (www.linkedin.com/company/ross-optical-industries/) (https://www.linkedin.com/company/lighthouse-imaging-corporation/) and Twitter feed (http://twitter.com/rossoptical) and on our Lighthouse Facebook page (https://www.facebook.com/lighthouseoptics/).

 

The information that we post on these social media channels could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in Precision Optics to review the information that we post on these social media channels. These social media channels may be updated from time to time on Precision Optics’ investor relations website. The information on, or accessible through, our websites and social media channels is not incorporated by reference in this Quarterly Report on Form 10-Q.

 

The markets in which we do business are highly competitive and include both foreign and domestic competitors. Many of our competitors are larger and have substantially greater resources than we do. Furthermore, other domestic or foreign companies, some with greater financial resources than we have, may seek to produce products or services that compete with ours. We routinely outsource specialized production efforts as required to obtain the most cost-effective production. Over the years we have developed extensive experience collaborating with other optical specialists worldwide.

  

We believe that our future success depends to a large degree on our ability to develop new optical products and services to enhance the performance characteristics and methods of manufacture of existing products. Accordingly, we expect to continue to seek and obtain product-related design and development contracts with customers and to selectively invest our own funds on research and development, particularly in the areas of MicroprecisionTM optics, micro medical cameras, illumination, single-use endoscopes and 3D endoscopes.

    

Current sales and marketing activities are intended to broaden awareness of the benefits of our new technology platforms and our successful application of these new technologies to medical device projects requiring surgery-grade visualization from sub-millimeter sized devices and 3D endoscopy, including single-use products and assemblies. We market directly to established medical device companies primarily in the United States that we believe could benefit from our advanced endoscopy visualization systems. Through this direct marketing, referrals, attendance at trade shows and a presence in online professional association websites, we have expanded our on-going pipeline of projects to significant medical device companies as well as well-funded emerging technology companies. We expect our customer pipeline to continue to expand as development projects transition to production orders and new customer projects enter the development phase. Our Ross Optical division markets through existing customers and trade shows, in addition to proactive online marketing strategies executed primarily through its website.

 

General

 

This management’s discussion and analysis of financial condition and results of operations is based upon our unaudited consolidated financial statements, which have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

   

There have been no significant changes in our critical accounting policies as disclosed in the Notes to our Financial Statements contained in our Annual Report on Form 10-K for the year ended June 30, 2022 filed with the Securities and Exchange Commission on September 27, 2022.

  

 

 

 15 

 

 

Results of Operations

 

Our total revenues for the quarter ended September 30, 2022, were $5,085,301, as compared to $2,336,344 for the same period in the prior year, an increase of $2,748,957, or 118%, primarily due to inclusion of the Lighthouse division since its acquisition in October, 2021 and an increase in medical device manufacturing and optical component revenue. Excluding the effect of the Lighthouse acquisition, component revenue increased 82%, production increased 37% and engineering revenue increased 18% from the quarter ended September 30, 2021 to 2022.

  

Our largest customer during the three months ended September 30, 2022 accounted for 16.6% of our revenue and represented component revenue for a defense/aerospace customer. We generated revenues from 194 unique customers during the three months ended September 30, 2022.

 

The COVID-19 world-wide pandemic that began during the quarter ended March 31, 2020 and the domestic and international impact of policy decisions being made in major countries around the world has had, and could continue to have, an adverse impact on our sources of supply, current and future orders from our customers, collection of amounts owed to us from our customers, our internal operating procedures, and our overall financial condition.

 

Gross profit for the quarter ended September 30, 2022 was $1,724,654, compared to $639,032 for the same period in the prior year, an increase of $1,085,622, or 170%. Gross profit for the quarter ended September 30, 2022 as a percentage of our revenues was 33.9%, an increase from the gross profit percentage 27.4% for the same period in the prior year. Quarterly gross profit and gross profit percentage depend on a number of factors, including overall sales volume, facility utilization, product sales mix, the costs of engineering services, production start-up costs and challenges in connection with new products, the effects of COVID-19 pandemic policy decisions on various economies and our suppliers and customers, as well as the effects on production efficiencies due to the augmented policies we have incorporated into our operations as a result of the COVID-19 pandemic.

 

Our gross profit on individual engineering projects is dependent on a number of factors and is expected to fluctuate from quarter to quarter based on the nature and status of engineering projects, unanticipated cost over-runs, design challenges and changes, start-up production activities, or other customer-imposed project changes or delays. Our increase in gross margin dollars during the quarter ended September 30, 2022 was due to inclusion of the Lighthouse division since its acquisition on October 4, 2021, an increase in both medical device manufacturing revenue and optical component revenue, and improved efficiencies in engineering projects, which is partially offset by inclusion of the Lighthouse division engineering and production revenues at overall margins lower than the Ross Optical division revenues. The remainder of our production, engineering and component revenues resulted in margins within our targeted range with reasonably expected fluctuations.

  

Research and development expenses were $245,477 for the quarter ended September 30, 2022, compared to $105,186 for the same period in the prior year, an increase of $140,291, or 133%. In-house research and development and certain internal functions not directly related to customer engagements are classified as research and development expenses with the majority of our engineering, research and development activities being consumed in revenue generating engagements with our customers for the development of their products. During the quarter ended September 30, 2022 we had an increase in research and development costs due to the inclusion of the Lighthouse division offset by a greater amount of our engineering personnel time consumed in customer focused compared to the same periods of the prior fiscal year. 

 

Selling, general and administrative expenses were $1,495,766 for the quarter ended September 30, 2022, compared to $933,624 for the same period in the prior year, an increase of $562,142, or 60.2%. The increase in selling, general and administrative expenses in the three months ended September 30, 2022 compared to the same periods of the prior fiscal year was primarily due to inclusion of the Lighthouse division since its acquisition in October, 2021, plus increased compensation due to expanded headcount and marketing related expenses.

 

 

 

 16 

 

 

Liquidity and Capital Resources

 

We have sustained recurring net losses from operations for several years. During the quarter ended September 30, 2022, and the years ended June 30, 2022 and 2021 we incurred operating losses of $16,589, $1,513,890 and $905,583, respectively. At September 30, 2022, cash was $673,502, accounts receivables were $3,414,685 and current liabilities were $5,192,420, including $1,032,891 of customer advances received for future order deliveries.

 

Although our revenue and gross margin have increased due to the acquisition of the Lighthouse division, our operating expenses have also increased, and we continue to experience pricing pressure from our customers and challenges in engineering projects and production orders that can result in cost over-runs and depressed gross margins. We also experience added uncertainty related to our vendors ability to supply materials and our customers future order levels as a result of the economic impact the COVID-19 world-wide pandemic and related jurisdictional policies and regulations and lingering supply-chain issues. Consequently, critical to our ability to maintain our financial condition is achieving and maintaining a level of quarterly revenues that generate break even or better financial performance as well as timely collection of accounts receivable from our customers. We believe profitable operating results can be achieved through a combination of revenue levels, realized gross margins and controlling operating expense increases, all of which are subject to periodic fluctuations resulting from sales mix and the stage of completion of varying engineering service projects as they progress towards and into production level revenues.

 

We have traditionally funded working capital needs through product sales, management of working capital components of our business, cash received from public and private offerings of our common stock, warrants to purchase shares of our common stock or convertible notes, manufacturing equipment leases, and by customer advances paid against purchase orders by our customers and recorded in the current liabilities section of the accompanying financial statements. We have incurred year to year and quarter to quarter operating losses during our efforts to develop current products including MicroprecisionTM optical elements, micro medical camera assemblies and 3D endoscopes. Our management believes that the opportunities represented by these technical capabilities and related products have the potential to generate sales increases to achieve breakeven and profitable results.

 

In connection with our October 2021 acquisition of Lighthouse Imaging, we entered into a $2,600,000 bank term loan, and sold shares of our common stock for gross proceeds of $1,500,000. We also secured a $250,000 bank line of credit from the same bank in October 2021 for working capital needs, which was increased to $500,000 in May 2022. There were no borrowings outstanding on the line of credit at September 30, 2022.

 

Capital equipment expenditures and additional patent costs during the three months ended September 30, 2022 were $29,174. Future capital equipment and patent expenditures will be dependent upon future sales and success of on-going research and development efforts.

  

Contractual cash commitments for the fiscal periods subsequent to September 30, 2022, are summarized as follows:

 

    Fiscal 2023   Thereafter   Total
Capital lease for equipment, including interest   $ 36,464     $ 120,564     $ 157,028  
Minimum operating lease payments   $ 136,167     $ 377,904     $ 514,071  

 

We have contractual cash commitments related to open purchase orders as of September 30, 2022 of approximately $3,252,770.

  

Off-Balance Sheet Arrangements

 

We currently have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

 

 

 17 

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

  

Item 4. Controls and Procedures.

 

Management’s Evaluation of Disclosure Controls and Procedures

 

Our Chief Executive Officer and our Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures, including internal control over financial reporting, were effective as of September 30, 2022, to ensure the information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (i) is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are intended to be designed to provide reasonable assurance that such information is accumulated and communicated to our management. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of September 30, 2022.

    

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting that occurred during the quarter of our fiscal year covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 18 

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Our Company, on occasion, may be involved in legal matters arising in the ordinary course of our business. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of operations. We are not aware of any pending or threatened litigation against us or our officers and directors in their capacity as such that could have a material impact on our operations or finances.

 

Item 1A. Risk Factors.

 

There have been no material changes from the risk factors previously disclosed in our annual report on Form 10-K for the fiscal year ended June 30, 2022, as filed with the Securities and Exchange Commission on September 27, 2022.

  

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

  

Item 5. Other Information.

 

As previously reported, the Company effected a 1-for-3 reverse split of its Common Stock as of 11:59 p.m. Eastern Time on Tuesday, November 1, 2022. The reverse stock split reduced the outstanding Common Stock from 16,915,089 shares to 5,638,302 shares, including the reduction for elimination of fractional shares. The total number of shares of Common Stock authorized under the Company’s Articles of Organization remains unchanged, at 50,000,000 shares, $.01 par value per share. The Common Stock began trading on a reverse stock split-adjusted basis on the OTCQB on November 2, 2022. The new CUSIP number for the Common Stock following the Reverse Stock Split is: 740294400.

 

 

 

 

 19 

 

 

Item 6. Exhibits.

 

Exhibit   Description
     
2.1   Asset Purchase Agreement between the Company and Optometrics Corporation, dated January 18, 2008 (included as Exhibit 2.1 to the Form 8-K filed January 25, 2008 and incorporated herein by reference).
     
3.1   Articles of Organization of Precision Optics Corporation, Inc., as amended (included as Exhibit 3.1 to the Form SB-2 filed March 16, 2007, and incorporated herein by reference).
     
3.2   Bylaws of Precision Optics Corporation, Inc. (included as Exhibit 3.2 to the Form S-1 filed December 18, 2008, and incorporated herein by reference).
     
3.3   Articles of Amendment to the Articles of Organization of Precision Optics Corporation, Inc., dated November 25, 2008 and effective December 11, 2008 (included as Exhibit 3.1 to the Form 8-K filed December 11, 2008, and incorporated herein by reference).
     
3.4   Amended and Restated Bylaws of Precision Optics Corporation, Inc. (included as Exhibit 3.1 to the Current Report on Form 8-K filed July 11, 2014, and incorporated herein by reference).
     
3.5  

Amendment to the Amended and Restated Bylaws of Precision Optics Corporation, Inc. effective May 13, 2022 (included as exhibit 3.5 to the Form 10-Q filed May 16, 2022, and incorporated herein by reference).

 

3.6   Articles of Amendment to the Articles of Organization of Precision Optics Corporation, Inc., dated October 24, 2022; and Articles of Amendment to the Articles of Organization of Precision Optics Corporation, Inc., dated October 26, 2022 (included as Exhibit 3.1 to the Form 8-K filed November 2, 2022, and incorporated herein by reference).
     
3.7   Articles of Amendment to the Articles of Organization of Precision Optics Corporation, Inc., dated October 27, 2022 (included as Exhibit 3.2 to the Form 8-K filed November 2, 2022, and incorporated herein by reference).
10.1   Precision Optics Corporation, Inc. 2011 Equity Incentive Plan, dated October 13, 2011 (included as Exhibit 10.2 to Form S-8 filed October 14, 2011, and incorporated herein by reference.)
     
10.2   Precision Optics Corporation, Inc. Amended 2011 Equity Incentive Plan, dated October 14, 2011, as amended on April 16, 2015 (included as Exhibit 10.1 to the Company’s Registration Statement on Form S-8 filed April 20, 2015, and incorporated herein by reference).
     
10.3   Compensation Agreement, by and among Precision Optics Corporation, Inc. and Joseph N. Forkey, dated August 2, 2018 (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 3, 2018, and incorporated herein by reference).
     
10.4†+   Asset Purchase Agreement dated July 1, 2019, between Precision Optics Corporation, Inc. and Ross Optical Industries, Inc. and the shareholders (included as Exhibit 10.1 to the Form 8-K filed on July 8, 2019, and incorporated herein by reference).

 

 

 

 20 

 

 

10.5   Form of Purchase Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated July 1, 2019 (included as Exhibit 10.2 to the Form 8-K filed on July 8, 2019, and incorporated herein by reference).
     
10.6   Form of Registration Rights Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated July 1, 2019 (included as Exhibit 10.3 to the Form 8-K filed on July 8, 2019, and incorporated herein by reference).
     
10.7   Employment Agreement, by and among Precision Optics Corporation. Inc. and Divaker Mangadu, dated July 1, 2019 (included as Exhibit 10.4 to the Form 8-K filed on July 8, 2019, and incorporated herein by reference).
     
10.8†   Employment agreement, by and among Precision Optics Corporation, Inc. and Jeff DiRubio, dated April 26, 2019 (included as Exhibit 10.16 to the annual report on Form 10-K filed on September 26, 2019, and incorporated herein by reference).
     
10.9+   Lease Agreement, by and among Precision Optics Corporation, Inc. and Texzona Industries Ltd. dated July 1, 2019 (included as Exhibit 10.17 to the annual report on Form 10-K filed on September 26, 2019, and incorporated herein by reference).
     
10.10   Employment Offer Letter Daniel S. Habhegger, dated December 2, 2019 (included as Exhibit 10.18 to the quarterly report on Form 10-Q filed on February 13, 2020, and incorporated herein by reference).
     
10.11   Form of Securities Purchase Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated April 14, 2020 (included as Exhibit 10.1 to the current report on Form 8-K filed on May 7, 2020, and incorporated herein by reference).
     
10.12   Form of Registration Rights Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated April 14, 2020 (included as Exhibit 10.2 to the current report on Form 8-K filed on May 7, 2020, and incorporated herein by reference).
     
10.13†+   Asset Purchase Agreement, dated October 4, 2021, by and among Precision Optics Corporation, Inc. and Lighthouse Imaging, LLC and Anania & Associates Investment Company, LLC (included as Exhibit 10.1 to the current report on Form 8-K filed on October 8, 2021, and incorporated herein by reference).
     
10.14   Form of Securities Purchase Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated October 4, 2021 (included as Exhibit 10.2 to the current report on Form 8-K filed on October 8, 2021, and incorporated herein by reference).
     
10.15   Form of Registration Rights Agreement, by and among Precision Optics Corporation, Inc. and several Investors, dated October 4, 2021 (included as Exhibit 10.3 to the current report on Form 8-K filed on October 8, 2021, and incorporated herein by reference).
     
10.16+   Loan Agreement dated October 4, 2021, by and among Precision Optics Corporation, Inc. and Main Street Bank (included as Exhibit 10.4 to the current report on Form 8-K filed on October 8, 2021, and incorporated herein by reference).
     
10.17   $250,000 Revolving Line of Credit Note dated October 4, 2021 (included as Exhibit 10.5 to the current report on Form 8-K filed on October 8, 2021, and incorporated herein by reference).

 

 

 

 21 

 

 

10.18   $2,600,000 Term Loan Note dated October 4, 2021 (included as Exhibit 10.6 to the current report on Form 8-K filed on October 8, 2021, and incorporated herein by reference).
     
10.19   Security Agreement dated October 4, 2021, by and among Precision Optics Corporation, Inc. and Main Street Bank (included as Exhibit 10.7 to the current report on Form 8-K filed on October 8, 2021, and incorporated herein by reference).
     
10.20   Director side letter agreement dated October 4, 2021 (included as Exhibit 10.8 to the current report on Form 8-K filed on October 8, 2021, and incorporated herein by reference).
     
10.21   Precision Optics Corporation, Inc. 2022 Equity Incentive Plan (included as Appendix B to the proxy statement on Form DEF14A filed on February 24, 2022, and incorporated herein by reference).
     
14.1   Precision Optics Corporation, Inc. Corporate Code of Ethics and Conduct (included as Exhibit 14.1 to the Form 10-K filed September 28, 2008, and incorporated herein by reference).
     
21.1   Subsidiaries of the Registrant (included as Exhibit 21.1 to the Form 10-K filed September 26, 2008, and incorporated herein by reference).
     
31.1*   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2*   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1*   Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS*   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104*  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*   Filed Herewith.
†   Certain portions of the agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.
+   The schedules to agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K.  The Company will furnish copies of any such schedules to the SEC upon request.

 

Copies of above exhibits not contained herein are available to any stockholder, upon written request to: Chief Financial Officer, Precision Optics Corporation, Inc., 22 East Broadway, Gardner, MA 01440.

 

 

 

 22 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  PRECISION OPTICS CORPORATION, INC.
     
Date: November 14, 2022 By: /s/ Joseph N. Forkey
    Joseph N. Forkey
   

Chief Executive Officer

(Principal Executive Officer)

     
     
Date: November 14, 2022 By: /s/ Daniel S. Habhegger
    Daniel S. Habhegger
   

Chief Financial Officer 

(Principal Financial Officer and Principal Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 23 

Precision Optics (QB) (USOTC:PEYE)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Precision Optics (QB) Charts.
Precision Optics (QB) (USOTC:PEYE)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Precision Optics (QB) Charts.